Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise
Compared to dulaglutide 1.5 mg, once-weekly semaglutide remains cost-effective for treating type 2 diabetes uncontrolled on metformin in China under the new negotiation price. However, limitations exist, including the reliance on SUSTAIN-7 data and the lack of specific utility data for the Chinese population.
Authors
- H Zhang (ORCID: https://orcid.org/0000-0003-2180-0122)
- Yiming Mu (ORCID: https://orcid.org/0000-0002-3344-3540)
- Huimin Zou (ORCID: https://orcid.org/0000-0002-6239-3335)
- Hao Hu (ORCID: https://orcid.org/0000-0001-9441-106X)
- Carolina Oi Lam Ung (ORCID: https://orcid.org/0000-0003-1915-5099)
- Xianwen Chen (ORCID: https://orcid.org/0009-0008-5903-8368)
- Qi Ni (ORCID: https://orcid.org/0000-0003-2303-218X)
- Yang Shen (ORCID: https://orcid.org/0000-0001-7497-9299)
- Ying Hu (ORCID: https://orcid.org/0000-0003-2763-580X)
- Yijun Li (ORCID: https://orcid.org/0000-0002-1699-1510)
Institutions
- Peking University (CN)
- University of Macau (MO)
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1007/s13300-025-01716-9
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29